Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tramadol hydrochloride, quantity: 200 mg - tablet, modified release - excipient ingredients: hypromellose; hydrogenated castor oil; maize starch; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; lactose monohydrate; colloidal anhydrous silica; povidone; magnesium stearate; sodium starch glycollate; colour - tramadol sandoz sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long term treatment. tramadol sandoz sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. tramadol sandoz sr is not indicated as an as-needed (prn) analgesia.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tramadol hydrochloride, quantity: 150 mg - tablet, modified release - excipient ingredients: sodium starch glycollate; lactose monohydrate; colloidal anhydrous silica; maize starch; hypromellose; microcrystalline cellulose; magnesium stearate; povidone; calcium hydrogen phosphate dihydrate; hydrogenated castor oil; colour - tramadol sandoz sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long term treatment. tramadol sandoz sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. tramadol sandoz sr is not indicated as an as-needed (prn) analgesia.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tramadol hydrochloride, quantity: 100 mg - tablet, modified release - excipient ingredients: hypromellose; lactose monohydrate; calcium hydrogen phosphate dihydrate; magnesium stearate; sodium starch glycollate; hydrogenated castor oil; povidone; microcrystalline cellulose; maize starch; colloidal anhydrous silica; colour - tramadol sandoz sr is indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long term treatment. tramadol sandoz sr is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. tramadol sandoz sr is not indicated as an as-needed (prn) analgesia.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tamoxifen citrate, quantity: 30.4 mg (equivalent: tamoxifen, qty 20 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; titanium dioxide; microcrystalline cellulose; povidone; hypromellose; macrogol 4000; magnesium stearate; sodium starch glycollate - treatment of breast cancer. ? tamoxifen sandoz is indicated for the treatment of breast cancer.,primary reduction of breast cancer risk ? tamoxifen sandoz is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).

Zimbabwe - engelsk - Medicines Control Authority

sandoz s.a pty ltd - amoxycillin; clavulanic acid - powder, for suspension; oral - 125; 31.25mg

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lacosamide, quantity: 150 mg - tablet, film coated - excipient ingredients: crospovidone; hyprolose; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - lacosamide sandoz (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.,paediatric patents weighing less than 50 kg should not receive lacosamide sandoz film-coated tablets. paediatric patients weighing less than 50 kg should be accurately dosed on a mg/kg basis with other lacosamide products.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lacosamide, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; crospovidone; hyprolose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black; indigo carmine aluminium lake - lacosamide sandoz (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.,paediatric patents weighing less than 50 kg should not receive lacosamide sandoz film-coated tablets. paediatric patients weighing less than 50 kg should be accurately dosed on a mg/kg basis with other lacosamide products.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lacosamide, quantity: 100 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; hyprolose; crospovidone; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - lacosamide sandoz (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.,paediatric patents weighing less than 50 kg should not receive lacosamide sandoz film-coated tablets. paediatric patients weighing less than 50 kg should be accurately dosed on a mg/kg basis with other lacosamide products.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lacosamide, quantity: 200 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; crospovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - lacosamide sandoz (lacosamide) tablets are indicated as: ? monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. ? add-on therapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older. ? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.,paediatric patents weighing less than 50 kg should not receive lacosamide sandoz film-coated tablets. paediatric patients weighing less than 50 kg should be accurately dosed on a mg/kg basis with other lacosamide products.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pirfenidone, quantity: 801 mg - tablet - excipient ingredients: pregelatinised starch; croscarmellose sodium; hyprolose; magnesium stearate; silicon dioxide; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - pirfenidone sandoz is indicated for the treatment of idiopathic pulmonary fibrosis (ipf).